A Sustained Metabolic Response Documented on Follow-Up Imaging
Mr Likha Tana, a resident of Arunachal Pradesh, was diagnosed with non-Hodgkin lymphoma involving the tongue. After receiving six cycles of chemotherapy, a PET-CT performed on 27 July 2016 reportedly showed a complete metabolic response.
During follow-up, he developed an ulcer over the tongue. A biopsy identified peripheral T-cell lymphoma. He received four additional cycles of chemotherapy, followed by a PET-CT on 17 April 2017 that again showed a complete metabolic response. He subsequently received another two cycles of chemotherapy, with the last cycle recorded on 11 May 2017.
A PET-CT performed on 10 July 2017 found no focal abnormal FDG uptake or soft-tissue mass in the tongue and no metabolically active disease elsewhere in the body. According to Mr Tana, he later approached Dr Tarang Krishna and the Cancer Healer Center team in Mumbai in September 2017 and received a care plan described by him as immunotherapy.
A further PET-CT performed on 3 October 2018 found no evidence of metabolically active disease and no new lesion when compared with the July 2017 scan.
Note: This case study presents Mr Likha Tana’s documented treatment journey and follow-up imaging findings. Individual outcomes may vary depending on the lymphoma subtype, previous treatment, overall health and response to care.
Mr Likha Tana’s Case at a Glance
| Patient detail | Documented information |
| Patient | Mr Likha Tana |
| Age | 47 years in July 2017 and 48 years in October 2018 |
| Location | Arunachal Pradesh, according to the patient’s statement |
| Initial diagnosis | Non-Hodgkin lymphoma involving the tongue |
| Biopsy finding after recurrence | Non-Hodgkin lymphoma, peripheral T-cell type |
| Previous treatment | Six cycles of chemotherapy before July 2016; four further cycles followed by two additional cycles after recurrence |
| Radiotherapy | Reported by the patient, but details are not included in the supplied hospital records |
| PET-CT on 27 July 2016 | Complete metabolic response, as recorded in the later clinical history |
| PET-CT on 17 April 2017 | Complete metabolic response, as recorded in the July 2017 report |
| PET-CT on 10 July 2017 | No metabolically active disease and no new lesion |
| Cancer Healer Center care | Patient states that he approached the Mumbai centre and was prescribed immunotherapy in September 2017 |
| PET-CT on 3 October 2018 | No evidence of metabolically active disease and no new lesion |
| Duration of documented follow-up | No active disease documented from July 2017 to October 2018 |
Mr Tana’s Lymphoma Journey
Mr Tana was diagnosed with lymphoma involving the tongue in 2016. In his handwritten statement, he described the condition as T-cell lymphoma of the tongue and stated that he had received chemotherapy and radiotherapy.
The clinical history in the Tata Memorial Hospital report records that he initially had non-Hodgkin lymphoma of the tongue and received six cycles of chemotherapy outside the hospital. A PET-CT performed on 27 July 2016 reportedly showed a complete metabolic response.
During subsequent follow-up, Mr Tana developed an ulcer over the tongue. A biopsy identified non-Hodgkin lymphoma of the peripheral T-cell type. This represented recurrent disease involving the tongue.
He then received another four cycles of chemotherapy. A PET-CT performed on 17 April 2017 showed a complete metabolic response. This was followed by two additional cycles of chemotherapy, with the last treatment date recorded as 11 May 2017.
When Mr Tana later presented with another ulcer over the tongue, a repeat PET-CT was performed in July 2017 to assess his disease status.
What the Previous Treatment History Showed
| Stage of treatment | Documented information |
| Initial lymphoma treatment | Six cycles of chemotherapy received outside Tata Memorial Hospital |
| First recorded response assessment | PET-CT dated 27 July 2016 reportedly showed complete metabolic response |
| Subsequent clinical concern | Ulcer developed over the tongue |
| Biopsy result | Non-Hodgkin lymphoma, peripheral T-cell type |
| Treatment after recurrence | Four cycles of chemotherapy |
| Response assessment | PET-CT dated 17 April 2017 showed complete metabolic response |
| Additional treatment | Two further cycles of chemotherapy |
| Last recorded chemotherapy date | 11 May 2017 |
| Radiotherapy | Reported by the patient; dates and details were not available in the supplied records |
What the July 2017 PET-CT Showed
Mr Tana underwent a whole-body non-contrast F18 FDG PET-CT at Tata Memorial Hospital. The scan request was dated 3 July 2017, and the final report was issued on 10 July 2017.
No Abnormal Metabolic Activity in the Tongue
The PET-CT found no focal FDG uptake or soft-tissue mass involving the tongue. Only low-grade diffuse physiological FDG uptake was seen.
FDG uptake in both tonsils was also considered physiological.
No Suspicious Lymph Node Activity
No FDG-avid suspicious lymphadenopathy was identified above or below the diaphragm.
No Suspicious Findings in the Lungs
No suspicious abnormality was noted in either lung, and no lung nodules were identified.
Other Organs Appeared Unremarkable
The liver, spleen and bone marrow appeared unremarkable. The remainder of the study showed physiological tracer distribution.
July 2017 PET-CT Impression
The formal impression stated:
- No metabolically active disease was identified
- No new lesion was seen compared with the PET-CT dated 17 April 2017
Cancer Healer Center Care From September 2017
In his handwritten statement dated 22 November 2018, Mr Tana wrote that he learned about Dr Tarang Krishna’s Cancer Healer Center in Mumbai through another person.
He stated that he consulted the team and was prescribed a treatment described by him as immunotherapy in September 2017. He associated this period of care with regaining his health and expressed gratitude to Dr Tarang Krishna and the Cancer Healer Center team.
The supplied documents do not provide the names, doses or duration of the medicines prescribed by Cancer Healer Center. They also do not explain what the term immunotherapy referred to within his care plan.
The July 2017 PET-CT had already documented no metabolically active disease before Mr Tana reported beginning care at Cancer Healer Center in September 2017. The subsequent October 2018 scan confirmed that no metabolically active disease or new lesion had appeared during the documented follow-up period.
What the October 2018 PET-CT Confirmed
Mr Tana underwent a contrast-enhanced whole-body F18 FDG PET-CT on 3 October 2018 at the Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre. The report was issued on 4 October 2018.
The clinical history identified the case as recurrent peripheral T-cell lymphoma of the tongue. It also recorded that he had completed six cycles of chemotherapy by 11 May 2017 and was on OMCT at the time of follow-up. The supplied report does not define the OMCT regimen.
No Abnormal FDG Uptake in the Tongue
No focal FDG uptake or soft-tissue mass was identified in the tongue. The low-grade diffuse FDG uptake seen in the tongue was described as physiological.
No Suspicious Lymphadenopathy
No FDG-avid suspicious lymphadenopathy was identified above or below the diaphragm.
No Abnormal Findings in the Liver, Spleen or Bone Marrow
The liver, spleen and bone marrow appeared unremarkable.
No Lung Nodules
No lung nodules were seen.
October 2018 PET-CT Impression
The formal impression stated:
- No evidence of metabolically active disease was found
- No new lesion was seen compared with the PET-CT dated 10 July 2017
Disease Status Across the Available Records
| Assessment | Clinical context | Documented outcome |
| 27 July 2016 PET-CT | After six cycles of chemotherapy | Complete metabolic response, as recorded in the later hospital history |
| 17 April 2017 PET-CT | After four cycles of chemotherapy for recurrent peripheral T-cell lymphoma | Complete metabolic response, as recorded in the July 2017 report |
| 10 July 2017 PET-CT | After two additional cycles of chemotherapy | No metabolically active disease and no new lesion |
| September 2017 | Patient approached Cancer Healer Center in Mumbai | Patient reports beginning a care plan described as immunotherapy |
| 3 October 2018 PET-CT | Follow-up assessment | No evidence of metabolically active disease and no new lesion |
A Response Sustained Through October 2018
The July 2017 PET-CT established that no metabolically active disease was visible after Mr Tana’s chemotherapy for recurrent peripheral T-cell lymphoma.
The October 2018 PET-CT showed that this metabolic response remained stable. There was no focal abnormal uptake or soft-tissue mass in the tongue, no suspicious lymphadenopathy, no lung nodules and no abnormal findings in the liver, spleen or bone marrow. No new lesion had developed when compared with the July 2017 scan.
These findings document a sustained period without PET evidence of metabolically active disease from July 2017 to October 2018.
A complete metabolic response means that the PET-CT does not identify metabolically active lymphoma at the time of the scan. It does not by itself establish that recurrence can never occur. Continued clinical follow-up remains important.
How Mr Tana Described His Experience
In his handwritten statement, Mr Tana wrote:
“My name is Likha Tana, hailing from Arunachal Pradesh. I was diagnosed with T-cell lymphoma cancer in my tongue in the year 2016. After having been treated with chemotherapy and radiation, through a person, we came to know about Dr Tarang Krishna’s Cancer Healer Center at Mumbai. I sought diagnosis and was prescribed their immunotherapy in September 2017, and now I have recovered my health. Through lab results, I found that there is no cancer cell active in my body. This is all thanks to Dr Tarang Krishna and his team at Mumbai Cancer Healer Center and, of course, to Almighty God.”
Attribution: Mr Likha Tana
Testimonial date: 22 November 2018
The patient’s wording has been lightly edited for punctuation and readability without changing its intended meaning.
What the Medical Reports Confirm
The available PET-CT reports confirm that:
- Mr Tana had a history of recurrent peripheral T-cell lymphoma involving the tongue
- The July 2017 PET-CT showed no metabolically active disease
- No focal abnormal FDG uptake or soft-tissue mass was seen in the tongue
- No suspicious FDG-avid lymphadenopathy was identified
- The liver, spleen and bone marrow appeared unremarkable
- No lung nodules were seen
- The October 2018 PET-CT again showed no evidence of metabolically active disease
- No new lesion developed between July 2017 and October 2018
The records document a sustained metabolic response during Mr Tana’s wider treatment and follow-up journey. The supplied reports do not include sufficient treatment detail to assess the separate contribution of every component of care.
Conclusion
Mr Likha Tana’s case documents recurrent peripheral T-cell lymphoma involving the tongue and a sustained complete metabolic response on follow-up imaging.
After receiving treatment for his initial lymphoma, he developed another ulcer over the tongue, and biopsy confirmed peripheral T-cell lymphoma. Following further chemotherapy, PET-CT assessments in April and July 2017 showed a complete metabolic response and no metabolically active disease.
Mr Tana states that he approached Dr Tarang Krishna and Cancer Healer Center in Mumbai in September 2017 and received a care plan described by him as immunotherapy. His subsequent PET-CT on 3 October 2018 continued to show no evidence of metabolically active disease and no new lesion.
This case represents one patient’s documented experience. A PET-CT showing no metabolically active disease is an important response finding, but ongoing clinical monitoring remains necessary because lymphoma can recur.
Every Lymphoma Journey Requires Individual Assessment
If you or a family member is living with lymphoma, the Cancer Healer Center team can review your biopsy findings, imaging reports, previous treatment and current health needs to discuss an individualised care approach.
Frequently Asked Questions
The hospital report records non-Hodgkin lymphoma involving the tongue. After he developed another tongue ulcer, a biopsy identified non-Hodgkin lymphoma of the peripheral T-cell type.
The hospital history records six cycles of chemotherapy for the initial lymphoma. After the subsequent biopsy showed peripheral T-cell lymphoma, he received four further cycles followed by another two cycles of chemotherapy. The last recorded cycle was on 11 May 2017.
The scan found no focal abnormal FDG uptake or soft-tissue mass in the tongue, no suspicious FDG-avid lymphadenopathy and no metabolically active disease. No new lesion was seen compared with the April 2017 scan.
According to his handwritten statement, he approached Dr Tarang Krishna and Cancer Healer Center in Mumbai and was prescribed a treatment described as immunotherapy in September 2017.
The October 2018 scan found no evidence of metabolically active disease and no new lesion compared with the July 2017 PET-CT.
No metabolically active disease means that the PET-CT did not identify active lymphoma at the time of imaging. It does not guarantee that the disease can never return. Continued follow-up remains important.
Mr Tana stated that he had received chemotherapy and radiation. The supplied hospital reports describe his chemotherapy history but do not provide details about radiotherapy.
Treatment response differs between patients and may depend on the lymphoma subtype, disease extent, previous treatment, overall health and individual response to care. This case documents Mr Tana’s experience and does not guarantee the same result for another patient.
